Dolutegravir

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Dolutegravir

Examples of brand names: Tivicay [EU/DE]

ATC code: J05AJ03

Main use (for orientation): HIV

Documented research summary

The cell study includes THC/propylene glycol/dolutegravir groups. It does not establish a clinical pharmacokinetic interaction; the highlighted dolutegravir effect concerns nicotine and is partly non-significant. A specific THC interaction remains insufficiently established.

Uncertainties and limitations

C6 rat glioma cells, gene expression rather than clinical endpoints. Dolutegravir details in methods/results contradict one another (200 nM versus 200 ng/ml); additional obvious typographical errors. No quantitative extrapolation. Missing data do not establish safety.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

THC – insufficient evidence

Finding ID: B0456

Type of result: Preclinical co-medication context without reliable isolated THC interaction evidence

Observation: Combination groups include THC and dolutegravir; no reliable specific THC–dolutegravir effect is established.

Mechanism: Gene-expression response to propylene glycol/THC with and without dolutegravir

Study type: Exploratory C6 rat glioma cell model

Context studied: 18-hour cell experiment; THC 10 µM. Dolutegravir details contradictory (200 nM/200 ng/ml). Rat arm without dolutegravir.

Clinical interpretation: Open research question, not a clinical combination decision.

Limitations and uncertainties: The highlighted dolutegravir finding concerns nicotine and is partly non-significant. No pharmacokinetics, no patients, contradictory methods; not adopted as clinical evidence.

Original sources for this finding: Nicotine, THC, and Dolutegravir Modulate E-Cigarette-Induced Changes in Addiction- and Inflammation-Associated Genes in Rat Brains and Astrocytes. [VE_MED_38002516]

References and access status

[VE_LABEL_D0326] TIVICAY PD (DOLUTEGRAVIR SODIUM) TABLET, FOR SUSPENSION TIVICAY (DOLUTEGRAVIR SODIUM) TABLET, FILM COATED [VIIV HEALTHCARE COMPANY]

Original source / bibliographic reference

Authors: Respective marketing authorisation holder; regulatory product information

Year: 2026

Source type: Product information / SmPC / US Prescribing Information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[VE_MED_38002516] Nicotine, THC, and Dolutegravir Modulate E-Cigarette-Induced Changes in Addiction- and Inflammation-Associated Genes in Rat Brains and Astrocytes.

Original source / bibliographic reference

Authors: Kulbe JR, Nguyen L, Le AA, Laird AE, Taffe MA, Nguyen JD, Fields JA.

Year: 2023

Source type: Journal Article

DOI: 10.3390/brainsci13111556

PMID: 38002516

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility